NASDAQ$TSHA
Taysha Gene Therapies Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Taysha Gene Therapies reported its Q3 2024 financial results, highlighting progress with the FDA on the regulatory pathway for TSHA-102 and FDA approval to use the pivotal product in REVEAL trials. The company's cash resources are expected to support operations into the fourth quarter of 2026.
- Advanced discussions with the FDA on trial design, endpoints, and potential use of natural history data for REVEAL trials.
- FDA approved the use of pivotal TSHA-102 product in REVEAL trials based on analytical comparability.
- Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials are expected in H1 2025.
- High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in initial patients, and IDMC approved continued enrollment in cohort two.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$1.79M
Forward guidance
Taysha anticipates safety and efficacy data from REVEAL trials in H1 2025 and expects current cash resources to support operations into Q4 2026.
Tailwinds
- Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (low dose; n=2) expected in the first half of 2025 for REVEAL Adolescent and Adult Trial
- Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (high dose; n=2) expected in the first half of 2025 for REVEAL Pediatric Trial
- Current cash resources will support planned operating expenses and capital requirements into the fourth quarter of 2026.
- Aligned with the FDA on the Company’s proposed meeting cadence to expedite the development and review of TSHA-102
- The FDA endorsed the intended commercial manufacturing process, proposed analytical methods, and corresponding qualification and validation plans, including mechanism of action potency release assays
Headwinds
- Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025
- Focus on objective measures that clinically capture functional gains
- Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (low dose; n=2) expected in the first half of 2025
- Safety and efficacy data in cohort two (high dose; n=3) and an update on safety and efficacy data in cohort one (high dose; n=2) expected in the first half of 2025
- Net loss for the three months ended September 30, 2024, was $25.5 million, or $0.1 per share
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro